European Heart Journal Supplements最新文献

Evolution of leadless pacemaker technology. 无铅起搏器技术的发展。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae101

Clemens Steinwender, Miguel A Leal

{"title":"Evolution of leadless pacemaker technology.","authors":"Clemens Steinwender, Miguel A Leal","doi":"10.1093/eurheartjsupp/suae101","DOIUrl":"10.1093/eurheartjsupp/suae101","url":null,"abstract":"Cardiac pacemakers have revolutionized the management of heart rhythm disorders since their introduction in the mid-20th century. They have played a crucial role in the management of several clinical conditions, from symptomatic bradyarrhythmia to electrical and/or mechanical dyssynchrony. Conventional cardiac pacemakers have significantly evolved over the last several decades. However, a critical limitation has been the presence of a generator pocket and endovascular leads connecting the pulse generator to cardiac tissue. While leads are essential to the pacemaker system by transmitting electrical impulses, they impose several significant risks that include venous thrombosis, device-associated endocarditis, and lead malfunction (mainly due to lead fracture, insulation failure, and macro- or micro-dislodgement), whereas the generator pocket can be the origin of a systemic device infection. The development of leadless pacemakers inaugurated a new era in cardiac pacing, eliminating many of the risks associated with traditional transvenous pacemakers. Leadless pacemakers are small, self-contained devices, which are fundamentally able to pace the heart without the need for a pocket and endovascular leads.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 2","pages":"ii39-ii46"},"PeriodicalIF":1.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term management of leadless pacemakers. 无导线起搏器的长期管理。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae119

Andrew Andreae, Alexander Breitenstein, Jonathan P Piccini

{"title":"Long-term management of leadless pacemakers.","authors":"Andrew Andreae, Alexander Breitenstein, Jonathan P Piccini","doi":"10.1093/eurheartjsupp/suae119","DOIUrl":"10.1093/eurheartjsupp/suae119","url":null,"abstract":"Leadless pacemakers (LPs) are increasingly being used to treat bradyarrhythmias, and end of service (EOS) management decisions are becoming increasingly important given finite battery lifespans. Two strategies have been adopted for device EOS: LP abandonment and LP removal. Certain scenarios including high degree of LP encapsulation and 'last expected' pacing devices favour LP abandonment, while other LP complications may necessitate device removal. When abandoning LP, clinicians must understand design, performance, and safety considerations for devices left in place. When removing LP, specialized tools and techniques have been developed, each varying by device manufacturer and model. Case reports and series on LP removal have elucidated how to overcome challenges that may arise during removal. Despite best practice techniques, complications can arise before and after removal. Current studies on LP EOS management are limited, and further studies are needed to help understand predictors of successful device removal and long-term sequelae of both strategies. The aim of this state-of-the-art review is to help clinicians understand current strategies and considerations for both LP abandonment and removal.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 2","pages":"ii26-ii38"},"PeriodicalIF":1.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The exciting and evolving journey of leadless pacing. 令人兴奋和不断发展的旅程无铅节奏。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae115

Mikhael F El-Chami, Clemens Steinwender

引用次数: 0

Applications of leadless pacing. 无铅起搏的应用。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae089

Larry Chinitz, Serge Boveda, Robin Richard-Vitton, Theofanie Mela

引用次数: 0

Leadless pacing in peri-procedural settings. 在手术过程中设置无铅起搏。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae093

Mikhael F El-Chami, Ryan Cunnane

引用次数: 0

Leadless pacing in young patients. 年轻患者的无铅起搏。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae090

Paul Richard Roberts, Saverio Iacopino

{"title":"Leadless pacing in young patients.","authors":"Paul Richard Roberts, Saverio Iacopino","doi":"10.1093/eurheartjsupp/suae090","DOIUrl":"10.1093/eurheartjsupp/suae090","url":null,"abstract":"Leadless pacing has been established as an effective and safe therapy. The majority of published data relates to an older population. However, this therapy may be particularly attractive for a younger (<40 years) population where the complications of transvenous devices can be enhanced. These include having leads in the vasculature for a longer period of time and the need for more generator changes over a longer time frame that may increase the rate of complications, e.g. infection. There is increasing evidence that leadless pacing is safe and effective in a younger population that may include specific patient groups such as those that require infrequent pacing, e.g. cardioinhibitory vasovagal syncope. Additionally, leadless pacing may be particularly suited to patients with adult congenital heart disease where conventional access with transvenous devices may be challenging. There are also some other groups such as neuromuscular disorders associated with conduction system disease that may benefit. The paediatric population is a further group that offers many challenges for pacing and so may be considered for leadless pacing. There is an increasing evidence base for the use of a superior jugular approach in this population rather than the conventional femoral approach. Further evidence to support leadless pacing would be enhanced with prospective randomized controlled studies in the population under the age of 40 years.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 2","pages":"ii14-ii20"},"PeriodicalIF":1.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ten years of leadless pacing. 十年无铅的踱步。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-03-24 eCollection Date: 2025-03-01 DOI: 10.1093/eurheartjsupp/suae102

Laurence M Epstein, Mikhael F El-Chami, Clemens Steinwender, Kyoko Soejima

引用次数: 0

Acute myocarditis: 2024 state of the art. 急性心肌炎：2024年最新进展。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae105

Enrico Ammirati, Iside Cartella, Marisa Varrenti, Adelina Selimi, Paola Sormani, Andrea Garascia, Matteo Palazzini

{"title":"Acute myocarditis: 2024 state of the art.","authors":"Enrico Ammirati, Iside Cartella, Marisa Varrenti, Adelina Selimi, Paola Sormani, Andrea Garascia, Matteo Palazzini","doi":"10.1093/eurheartjsupp/suae105","DOIUrl":"10.1093/eurheartjsupp/suae105","url":null,"abstract":"Acute myocarditis (AM) is an inflammatory injury of the myocardium secondary to infections, systemic autoimmune disorders, medications, or toxic agents. The patient's genetic underground is a likely concurrent aetiology/contributory mechanism recently implicated in a proportion of AM. This review focuses on some critical new concepts of AM, updated indications for endomyocardial biopsy when cardiac magnetic resonance imaging is not sufficient or feasible, and estimation of long-term events after discharge. Furthermore, studies exploring AM as the cause of sudden cardiac death will be examined to assess the characteristics of patients who die due to AM before hospital admission. Managing the most severe clinical presentation, termed fulminant myocarditis (FM) characterized by haemodynamic instability due to ventricular arrhythmias or severe acute pump failure, will be summarized. Specific issues aimed to reduce the high mortality rate of FM, like early recognition, referring these patients from spoke centres to a hub centre, timely temporary mechanical circulatory support when indicated, early endomyocardial biopsy, and eventually immunosuppression, will be briefly discussed. Immune checkpoint inhibitors and desmosomal gene variant-associated AM will be highlighted as paradigmatic new forms of myocarditis.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i56-i60"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Periodic breathing during exercise in heart failure: beyond the classic risk factors. 运动期间周期性呼吸对心力衰竭的影响：超越经典危险因素。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae091

Marlus Karsten, Elisabetta Salvioni, Pietro Palermo, Irene Mattavelli, Marco Scatigna, Massimo Mapelli, Giulia Grilli, Beatrice Pezzuto, Anna Apostolo, Gustavo Dos Santos Ribeiro, Piergiuseppe Agostoni

{"title":"Periodic breathing during exercise in heart failure: beyond the classic risk factors.","authors":"Marlus Karsten, Elisabetta Salvioni, Pietro Palermo, Irene Mattavelli, Marco Scatigna, Massimo Mapelli, Giulia Grilli, Beatrice Pezzuto, Anna Apostolo, Gustavo Dos Santos Ribeiro, Piergiuseppe Agostoni","doi":"10.1093/eurheartjsupp/suae091","DOIUrl":"10.1093/eurheartjsupp/suae091","url":null,"abstract":"Periodic breathing is a peculiar ventilatory pattern in patients with heart failure (HF), characterized by cyclic oscillations in minute ventilation. This phenomenon has been observed in awake patients, during sleep, and during exercise. Periodic breathing during exercise, also known as exercise oscillatory ventilation (EOV), is an important marker of clinical and functional status, morbidity, and mortality in HF patients. However, a clear understanding of the meaning, causes, and possible occurrence of different forms of EOV is still currently lacking. This review focuses on what is known, likely known, or unknown about EOV in HF, including topics such as the definition of EOV, pathophysiological mechanisms, EOV phenotypes, treatment modalities, and the prognostic role of EOV in patients with HF. Finally, some perspectives on research opportunities and clinical practice are presented, to increase the knowledge of EOV, and the application of tools for its assessment, which may improve the chances of identifying and treating EOV, with a positive impact on patients with HF.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i103-i108"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Left atrial appendage occlusion: behind the bleeding risk. 左心耳闭塞：后方出血风险。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae094

Giovanni Lorenzoni, Pierluigi Merella, Gavino Casu

引用次数: 0